Notably, CD44 (2.45-fold, P < 0.001), CD133 (3.03-fold, P < 0.001), and Nanog (2.32-fold, P < 0.001) levels were markedly reduced in treated glioma cells with an IC50-value of CER compared to the control. This evidence concerns the gene CD44 and glioma.